PORTFOLIO BREAKDOWN

FREE PREVIEW

THE CORE ETFs (NEVER SELL)

These are my foundation. Every M&A win → 60% goes here. 10-year retirement timeline = 70/30 stocks/bonds.

QQQM - 26% - Invesco Nasdaq 100 - $251.14 - Nasdaq Growth, tech exposure

VTI - 23% - Vanguard Total Stock Market - $333.90 - Total US Market, owns everything

SCHD - 15% - Schwab US Dividend Equity - $27.49 - Dividend Growth, quality + income

VYM - 9% - Vanguard High Dividend Yield - $144.56 - 200+ holdings, 2-3% yield

VXUS - 8% - Vanguard Total International - $75.78 - International exposure

JEPQ - 8% - JPMorgan Nasdaq Premium Income - $58.01 - 10.22% yield from covered calls

VTV - 6% - Vanguard Value - $191.36 - Value stocks (selling after Dec 22 ex-div)

SGOV - 4% - iShares 0-3 Month Treasury - $100.54 - Cash/T-Bills, safe parking

BND - 4% - Vanguard Total Bond Market - $74.28 - Bonds, ballast for volatility

Total Core ETFs: ~$274,954

---

🌿 WEED ETFs (SHORT-TERM TRUMP TRADE)

Trump rumored to sign pot order - these are NOT long-term holds. Selling the news.

WEED - $28.34 - +21.01% today - Roundhill Cannabis ETF

MSOS - $6.39 - +19.42% today - AdvisorShares Pure US Cannabis

YOLO - $4.17 - +15.51% today - AdvisorShares Pure Cannabis

Strategy: Ride the Trump rumor hype → (sell the news)

---

💊 UNDER $10 HOLDINGS (FREE PREVIEW)

Full M&A analysis + $10+ holdings = PAID ONLY 🔒

IXHL - $0.41 - +7.45% - Cannabis pharma (Australia)

IMUX - $0.61 - -1.42% - Autoimmune (selective oral immunology)

RVPH - $0.62 - -1.05% - Schizophrenia (combo therapy)

PSTV - $0.63 - +1.01% - Brain cancer (ReSPECT trial)

NRSN - $0.84 - +0.76% - ALS (ALS-Wellness trial)

FEMY - $0.86 - -0.84% - Women’s health (FemBloc)

CRDL - $1.02 - -0.97% - Cardiology (cannabinoid therapy)

ONCY - $1.05 - +13.76% - Oncolytic virus (pelareorep)

CNTX - $1.08 - -4.42% - Ovarian cancer (claudin 6 ADC)

FATE - $1.09 - -2.70% - iPSC cell therapy

HUMA - $1.13 - -4.24% - Vascular grafts (FDA approved)

PLRX - $1.27 - +2.40% - Fibrosis (integrin inhibitor)

MRKR - $1.30 - -6.47% - T-cell therapy (solid tumors)

BMEA - $1.38 - +2.99% - Obesity (covalent menin inhibitor)

MDAI - $1.51 - +1.34% - AI wound care

ALLO - $1.52 - +3.40% - AlloCAR-T (off-the-shelf)

OVID - $1.57 - +0.64% - Rare epilepsy (soticlestat)

AKBA - $1.62 - +0.62% - Kidney disease (profitable!)

AUTL - $1.63 - +0.62% - CAR-T lupus (83% remission)

OSTX - $1.69 - +1.20% - Osteosarcoma

CRBU - $1.70 - -0.58% - CRISPR CAR-T

MDCX - $1.84 - +0.55% - Oncology (Israel)

NKTX - $1.85 - +0.73% - NK cell therapy

IBRX - $2.14 - -3.50% - Immunotherapy (Anktiva approved)

IRD - $2.14 - +0.47% - Gene therapy (IRD)

MIST - $2.22 - -5.33% - Cardiovascular (FDA approved 12/13)

IOVA - $2.25 - +4.17% - TIL therapy (lifileucel approved)

SLS - $2.25 - +10.25% - GPS cancer therapy

CCCC - $2.29 - -5.76% - Protein degradation

ACRV - $2.39 - -7.00% - Precision oncology (ACR-368)

CABA - $2.39 - 0.00% - CAAR-T autoimmune (MS, lupus)

IMMP - $2.45 - +0.55% - Immunotherapy (efti)

CHMI - $2.60 - +4.00% - Mortgage REIT (5.88% dividend)

BDTX - $2.65 - 0.00% - Precision oncology (EGFR)

CATX - $2.80 - +10.24% - Radiopharmaceuticals

OKUR - $2.95 - -7.81% - Oncology (KRAS inhibitor)

ACRS - $3.23 - +1.89% - Dermatology + oncology

ABSI - $3.54 - +4.42% - AI drug discovery platform

GOSS - $3.60 - -5.01% - Autoimmune (seralutinib)

ANIX - $3.75 - +14.97% - Ovarian cancer vaccine

GANX - $3.89 - -1.40% - Parkinson’s (GBA1 gene therapy)

NEUP - $3.89 - +1.68% - Depression (NMDA modulator)

PYPD - $3.95 - -1.25% - Antibiotic implant

ATAI - $4.21 - +1.69% - Psychedelics (mental health)

CLYM - $4.50 - +18.13% - Rare disease (budoprutug)

FHTX - $4.53 - +3.66% - Oncology (chromatin regulation)

IVA - $4.66 - +4.02% - NASH (lanifibranor)

ABUS - $4.75 - -4.05% - Hepatitis B cure

DRTS - $5.04 - -1.37% - Cancer radiotherapy (Alpha DaRT)

ALT - $5.09 - -3.60% - Obesity (pemvidutide)

ALDX - $5.24 - +31.33% - Dry eye (reproxalap)

CMPX - $5.34 - +5.12% - IO-Mab antibodies

TSHA - $5.80 - +0.69% - Gene therapy (Rett, GM2)

AQST - $5.84 - -1.18% - Oral film delivery (epinephrine)

FFWM - $6.09 - -0.81% - Regional bank (M&A target)

CLNN - $6.31 - +1.12% - ALS/MS (CNM-Au8)

VIR - $6.51 - -3.12% - Hepatitis Delta (66% undetectable)

ALAR - $7.32 - +0.83% - Cybersecurity (NetNut)

TLSI - $7.41 - +1.37% - Liver cancer (pressure-enabled delivery)

BCRX - $7.50 - -1.19% - Rare disease (berotralstat approved)

LNKB - $8.41 - -1.29% - Regional bank (M&A target)

KLRS - $8.49 - -0.12% - Allogeneic cell therapy

OMER - $8.79 - -4.46% - Rare disease + Novo deal

TNGX - $8.96 - -1.75% - Oncology (PRMT5 inhibitor, Nobel founder)

FNWB - $9.95 - -0.30% - Regional bank (M&A target)

Breakdown & more in Sunday night news